All In Biotech

Drug Trial Radar · NCT06590324

A Study of Apabetalone in Subjects With Long -COVID

A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)

Last checked: Nov 19, 2026Latest source record: Apr 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

Dec 30, 2025

Study completion Mar 30, 2026

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.

Conditions

  • Post-Acute COVID-19 Syndrome

Interventions

  • ApabetaloneDrug

    100-mg capsule, twice daily oral administration with meals

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. patient acceptable symptom state (PASS)Time frame: 90 days

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • The Speciality Hospital

    Amman, Jordan · Not yet recruiting

  • MNGHA- King Abdulaziz Hospital

    Al Mubarraz, Saudi Arabia · Not yet recruiting

  • Al Kuwait Hospital

    Dubai, Dubai, United Arab Emirates · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.